Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $27.0 million.

  • Indivior Pharmaceuticals' Other Non-Current Assets fell 1562.5% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 1562.5%. This contributed to the annual value of $39.0 million for FY2024, which is 833.33% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Other Non-Current Assets of $27.0 million as of Q3 2025, which was down 1562.5% from $44.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Other Non-Current Assets ranged from a high of $106.0 million in Q4 2021 and a low of $27.0 million during Q3 2025
  • Over the past 5 years, Indivior Pharmaceuticals' median Other Non-Current Assets value was $39.0 million (recorded in 2024), while the average stood at $48.3 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Other Non-Current Assets crashed by 6631.58% in 2024, and later surged by 3333.33% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Other Non-Current Assets stood at $106.0 million in 2021, then crashed by 64.15% to $38.0 million in 2022, then dropped by 5.26% to $36.0 million in 2023, then increased by 8.33% to $39.0 million in 2024, then crashed by 30.77% to $27.0 million in 2025.
  • Its last three reported values are $27.0 million in Q3 2025, $44.0 million for Q2 2025, and $39.0 million during Q1 2025.